Iman Abou Dalle

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5516255/publications.pdf

Version: 2024-02-01

1307594 1058476 16 304 7 14 citations g-index h-index papers 16 16 16 403 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	20-Year Steady Increase in Survival of Adult Patients with Relapsed Philadelphia-Positive Acute Lymphoblastic Leukemia Post Allogeneic Hematopoietic Cell Transplantation. Clinical Cancer Research, 2022, 28, 1004-1012.	7.0	12
2	Safety and Efficacy of Elective Switch from Nilotinib to Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia. Clinical Hematology International, 2022, 4, 30-34.	1.7	1
3	Phase 2 study of lenalidomide maintenance for patients with highâ€risk acute myeloid leukemia in remission. Cancer, 2021, 127, 1894-1900.	4.1	5
4	The use of intrathecal chemotherapy and dexamethasone for secondary prevention of blinatumomab-related neurotoxicity. Current Research in Translational Medicine, 2021, 69, 103285.	1.8	7
5	Risk adapted therapeutic strategy in newly diagnosed acute myeloid leukemia: Refining the outcomes of ELN 2017 intermediate-risk patients. Leukemia Research, 2021, 105, 106568.	0.8	3
6	Intrathecal methotrexate induced myelopathy, rare yet serious complication: A case report and review of the literature. Current Research in Translational Medicine, 2021, 69, 103296.	1.8	4
7	First-Line Treatment of Hairy Cell Leukemia with Cladribine Followed by Rituximab Consolidation Significantly Improves Leukemia-Free Survival. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 564-566.	0.4	0
8	The Use of Voriconazole as Primary Prophylaxis for Invasive Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation: A Single Center's Experience. Journal of Fungi (Basel,) Tj ETQq0 0 0 rgB	T (Ds verloc	ck 1 0 Tf 50 45
9	Impact of luteinizing hormone suppression on hematopoietic recovery after intensive chemotherapy in patients with leukemia. Haematologica, 2021, 106, 0-0.	3. 5	6
10	Successful lenalidomide treatment in high risk myelodysplastic syndrome with germline <i>DDX41</i> mutation. American Journal of Hematology, 2020, 95, 227-229.	4.1	29
11	Evaluation of Trends and Prognosis Over Time in Patients with AML Relapsing After Allogeneic Hematopoietic Cell Transplant Reveals Improved Survival for Young Patients in Recent Years. Clinical Cancer Research, 2020, 26, 6475-6482.	7.0	40
12	Impact of numerical variation, allele burden, mutation length and co-occurring mutations on the efficacy of tyrosine kinase inhibitors in newly diagnosed FLT3- mutant acute myeloid leukemia. Blood Cancer Journal, 2020, 10, 48.	6.2	22
13	Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with <i>FLT3</i> -internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica, 2020, 105, 1507-1516.	3.5	91
14	Philadelphia chromosomeâ€positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors. American Journal of Hematology, 2019, 94, 1388-1395.	4.1	26
15	Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States. Cancer Medicine, 2019, 8, 6559-6565.	2.8	24
16	Prognostic significance of baseline <i>FLT3</i> â€ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib. American Journal of Hematology, 2019, 94, 984-991.	4.1	32